Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:36:19 EDT Thu 03 Oct 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:XFOR - X4 PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XFOR - Q7.00.609·0.6537.00.6297+0.02033.3760.83961,5190.6161  0.6539  0.6051.60  0.531118:44:24Oct 0115 min RT 2¢

Recent Trades - Last 10 of 1519
Time ETExPriceChangeVolume
18:44:24Q0.650.0406105
17:19:29Q0.64170.032316
16:29:48Q0.62970.02038,680
16:20:00Q0.62970.02031,283
16:02:57Q0.62970.02034,333
16:02:35Q0.62970.02033,627
16:02:23Q0.62970.0203444
16:00:52Q0.64160.03222
16:00:29Q0.64160.032250
16:00:01Q0.62970.02031,093

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-03 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-28 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
2024-08-08 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-30 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
2024-06-27 06:30U:XFORNews ReleaseX4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
2024-06-03 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-29 16:30U:XFORNews ReleaseX4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
2024-05-13 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
2024-05-09 06:30U:XFORNews ReleaseX4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
2024-05-07 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
2024-05-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-30 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
2024-04-29 06:30U:XFORNews ReleaseX4 Pharmaceuticals Announces FDA Approval of XOLREMDI(TM) (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
2024-04-02 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-01 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
2024-03-21 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
2024-03-12 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
2024-03-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)